Bispecific nanobody KB-V13A12 bridges VWF to albumin and consequently attenuates normal VWF clearance in vivo, leading to a significant increase in endogenous plasma VWF levels. Figure created with BioRender.com. O'Donnell J.S. (2025) https://app.biorender.com/illustrations/689efc486cb58b1325e4a189.

Bispecific nanobody KB-V13A12 bridges VWF to albumin and consequently attenuates normal VWF clearance in vivo, leading to a significant increase in endogenous plasma VWF levels. Figure created with BioRender.com. O'Donnell J.S. (2025) https://app.biorender.com/illustrations/689efc486cb58b1325e4a189.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal